Trials / Unknown
UnknownNCT01670513
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Dow Pharmaceutical Sciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area affected will be enrolled in the study.
Detailed description
Approximately 60 subjects with a clinical diagnosis of moderate or severe psoriasis (defined as at least of 10 % - 20% treatable Body Surface Area (BSA) and an Investigator's Global Evaluation (IGE) of 3 or 4 at baseline (moderate or severe) will be enrolled in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDP-118 Low Strength | 8 weeks |
| DRUG | IDP-118 High Strength | 8 weeks |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-05-01
- Completion
- 2013-07-01
- First posted
- 2012-08-22
- Last updated
- 2013-04-25
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01670513. Inclusion in this directory is not an endorsement.